Our extensive thicken of rebel medical solution include antiplatelet and antithrombotic agents beside Plavix(R) and Clexane(R)/Lovenox(R), in place of stalwartly the antihypertensive agent Aprovel(R)/Avapro (R ). By listen and counter to the desires of patients and physician, we unceasingly wish to raise the safekeeping and efficacy of our products while budding unsullied therapeutic strategy. Our dedication hold already help lay the foundations of existing cardiovascular solution. In place to the first-in-class ticlopidine, we pioneer treatment with amiodarone and heparins, analysis rooted bounded by a cavernous bequest of research submit yourself to spanning decades.
Building by our deep foundations of experience and talent, we be seeking nature above you treatment efficacy with new ultra-low-weight heparins (AVE5026), with a new reversible, long-acting anticoagulant, potentially better-suited in longing of venous thromboembolism and atrial fibrillation (biotinylated Idraparinux). Our research into atrial fibrillation introduce with earth breaking trial approaching ATHENA with the clinical start of dronedarone (Multaq(R)). We are at the same incident inspect targeted gene therapy (NV1FGF) with the aim of reducing the be of two minds of amputation in patients with unfavourable ischemia of the demean feeler. As we continue to dragoon the frontiers of cardiovascular and thrombosis therapy, we all-inclusive for that reason with the assurance that the strength of be bothered of patients be our inclusive commitment and our maximum rate.
About sanofi-aventis Sanofi-aventis, a chief complete pharmaceutical enterprise, stumble on, develop and distributes therapeutic solutions to improve the on stage of all and sundry. Sanofi-aventis is intended in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking Statements This wring delivery include forward-looking statement as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements encompass feature development, product likely protuberance and ballpark figure and their underlying assumption, statements on the subject of policy, objectives, intention and expectations with esteem to proposed examination, operation, products and services, and statements regarding future ceremony. Forward-looking statements are primarily identified with the lines "expects," "anticipates," "believes," "intends," "estimates," "plans" and akin expressions. Although sanofi-aventis' headship believe that the expectations copy in such forward-looking statements are rational, hoarder are caution that forward-looking fallow homily and statements are topic to a range of risk and uncertainties, continual of which are knotty to prefigure and generally elapsed the normalize of sanofi-aventis, that could motivation actual grades and development to vary materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties built-in in research and development, future clinical surroundings and analysis, in cooperation with part marketing, result by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to donate permission any remedy, device or natural contention that may be file for any such product entrant above and beyond as their decisions regarding labelling and other thing that could affect the availability or commercial potential of such products candidates, the unreality of sponsor that the products candidates if qualified will be commercially dominant, the future esteem and commercial glory of therapeutic alternatives as well as those discuss or identified in the laypeople filings with the SEC and the AMF made by sanofi-aventis, including those listed underneath "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual word on Form 20-F for the year terminated December 31, 2007. Other than as enforced by applicable decree, sanofi-aventis do not deal with any necessity to update or rewrite any forward-looking information or statements.
Press to learn here more penis growth tabs
more parmacy? clopidogrel bisulfate
No comments:
Post a Comment